AzurRx BioPharma announced today that it has reached the sixth patient enrollment point in the ongoing 12-15 patient open-label Phase IIa trial of MS1819.

AzurRx BioPharma (NASDAQ:AZRX) announced today that it has reached the sixth patient enrollment point in the ongoing 12-15 patient open-label Phase IIa trial of MS1819.
As quoted in the press release:

AzurRx expects to report data from the first six patients in this study in September 2017.
While enrollment in the Phase IIa trial has been slower than anticipated, in order to further support enrollment in both this study and other planned future trials, AzurRx has added an additional clinical site in Australia.
“We are pleased to reach this point in enrollment of this important clinical trial,” said Thijs Spoor, CEO of AzurRx BioPharma. The additional clinical site in Australia is expected to drive enrollment in both this study and other future planned clinical trials. Following the positive interim data we reported in the second quarter on the first three patients in the Phase IIa study, we look forward to the availability of additional results from the first six patients in September.”

Click here to read the full press release.

Source: globenewswire.com

australia biopharma clinical trials enrollment patient patient enrollment patients trials Pharmaceutical Investing